Rethinking Medications: From Academic Detailing to Broken Drug Regulation | Jerry Avorn | EP 6

Pharma's Worst Job Market in 30 Years: Top Recruiter Reveals What to Do Now | Grant Coren | EP 7

In this episode of The Pharma Perspective podcast, Grant Coren, life science recruiter with over 30 years of experience and founder of his own executive search practice, discusses the state of the pharma job market in 2026, why hiring has slowed across pharma, biotech, and CRO alike, how AI screening tools and applicant tracking systems are changing — and distorting — the recruitment process, why most CVs fail to differentiate candidates and what to do instead, the ethical problems with how many recruiters operate and how job seekers should navigate that, the difference between retained executive search and contingency recruitment, how indirect referencing allows recruiters to vet candidates outside of formal references, why loyalty is no longer rewarded in pharma careers and when job-hopping actually accelerates progression, the personality traits that predict success in different pharma roles, the real impact of ageism in life sciences hiring, and why getting your first job in the industry remains the hardest step of all.

Rethinking Medications: From Academic Detailing to Broken Drug Regulation | Jerry Avorn | EP 6

In this episode of The Pharma Perspective podcast, Jerry Avorn, Professor of Medicine at Harvard Medical School and author of "Rethinking Medications," discusses the state of drug regulation in the United States, the problems with accelerated approvals and missing confirmatory trials, how academic detailing can change prescribing behavior more effectively than guidelines, the misuse of surrogate endpoints in drug development, why weak FDA enforcement actually harms pharmaceutical innovation, the absence of cost-effectiveness analysis and health technology assessment in US drug policy, and where he sees hope for reform through state-level drug policy coalitions and evidence-based prescribing initiatives.

Measuring What Patients Actually Care About | Katja Rüdell | EP 5

In this episode of The Pharma Perspective podcast, Katja Rüdell, one of the world's leading clinical outcome assessment and patient-reported outcomes experts, discusses the role of PROs in drug development, regulatory expectations from FDA and EMA for outcome measure validation, the challenges of developing fit-for-purpose COA instruments, the evolution of patient-centred research in pharmaceutical clinical trials, and best practices for ensuring PRO data meets both regulatory and clinical standards.

What Does the ABPI Actually Do? | Jack Neill-Hall | EP 4

In this episode of The Pharma Perspective podcast, Jack Neill-Hall from the Association of the British Pharmaceutical Industry (ABPI) discusses the UK pharmaceutical pricing environment, NICE's cost-effectiveness threshold and appraisal process for NHS medicines, industry transparency through the Code of Practice and Disclosure UK, healthcare budget allocation, and why some medicines never reach UK assessment.

Is Raising the NICE Threshold Bad for NHS Patients? | Karl Claxton | EP 3

In this episode of "The Pharma Perspective", I speak with Karl Claxton, Professor of Economics at the University of York and founding NICE Appraisal Committee member, about his open letter to the UK Prime Minister on pharmaceutical pricing for branded medicines, why raising the NICE willingness-to-pay threshold would be catastrophic for NHS patients, and his proposals for fundamentally reforming health technology assessment and how we value pharmaceutical innovation. 💷🏥